Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
MeiraGTx Holdings plc logo

NASDAQ · MGTX

MeiraGTx Holdings plc

Healthcare · Biotechnology

$12.79

Down-$0.06 (-0.47%)

Updated Sep 12, 2026, 6:42 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
701.08M
P/E ratio
-4.18
Dividend yield
0.00%
52-week range
$6.62 – $15.35
Volume
459.55K
Avg. volume
497.35K

Price performance

MGTX price history

1M range · 0 trading sessions · Daily adjusted prices

MGTX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MGTX news

The latest Smart Investors Daily articles mentioning MGTX.

Stock researchCompany · Overview

MGTX research

Overview

Company profile and research snapshot.

Company profile

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
MGTX recent ratings
DateFirmRatingTarget
Aug 14, 2026RBC CapitalOutperform—
Jul 8, 2026RBC CapitalOutperform—
Jul 8, 2026HC Wainwright & Co.Buy—
May 15, 2026RBC CapitalOutperform—
Apr 22, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 26, 2026

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a multicenter Phase Ib/II multi-dose, open-label clinical trial evaluating the safety, tolerability, and efficacy of GV101 in patients with moderate to severe chronic Graft versus Host Disease (cGvHD). The data, published in Signal Transduction and Targeted Therapy, a Springer Nature Portfolio journal, provide efficacy and findings from the 60 enrolled pat

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By